Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Ранг среди акций #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Цена акции
$193.62
Рыночная капитализация
$150.08B
Изменение (1 день)
2.76%
Изменение (1 год)
184.69%
Страна
GB
Торговля AstraZeneca PLC (AZN)

Категория

Операционная маржа для AstraZeneca PLC (AZN)
Операционная маржа на April 2026 TTM: 23.28%
Согласно последним финансовым отчетам и цене акций AstraZeneca PLC, текущая операционная маржа (TTM) составляет 23.28%. В конце 2023 она составила 20.54%.
История операционной маржи AstraZeneca PLC с 2000 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
2026 (TTM) 23.28% -1.56%
2024 23.65% 15.14%
2023 20.54% 80.02%
2022 11.41% 50.73%
2021 7.57% -55.42%
2020 16.98% 47.52%
2019 11.51% 38.51%
2018 8.31% -46.21%
2017 15.45% -0.26%
2016 15.49% 6.90%
2015 14.49% 3.95%
2014 13.94% -41.77%
2013 23.94% -24.38%
2012 31.66% -12.49%
2011 36.18% -4.69%
2010 37.96% 8.15%
2009 35.10% 11.39%
2008 31.51% 11.78%
2007 28.19% -3.85%
2006 29.32% 9.73%
2005 26.72% 31.24%
2004 20.36% -6.65%
2003 21.81% -10.69%
2002 24.42% 1.79%
2001 23.99% 18.59%
2000 20.23% 0.00%
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
45.56% -98.04%
US
27.17% -98.83%
US
26.72% -98.85%
US
31.24% -98.66%
CH
41.19% -98.23%
US
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.